Pleura and Peritoneum最新文献

{"title":"ISSPP CONGRESS 2022 3RD CONGRESS OF THE INTERNATIONAL SOCIETY FOR THE STUDY OF PLEURA AND PERITONEUM.","authors":"","doi":"10.1515/pp-2023-0010","DOIUrl":"https://doi.org/10.1515/pp-2023-0010","url":null,"abstract":".","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 1","pages":"A1-A47"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9307236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival benefits with EPIC in addition to HIPEC for low grade appendiceal neoplasms with pseudomyxoma peritonei: a propensity score matched study.","authors":"Raymond Hayler,&nbsp;Kathleen Lockhart,&nbsp;Shoma Barat,&nbsp;Ernest Cheng,&nbsp;Jasmine Mui,&nbsp;Raphael Shamavonian,&nbsp;Nima Ahmadi,&nbsp;Nayef Alzahrani,&nbsp;Winston Liauw,&nbsp;David Morris","doi":"10.1515/pp-2022-0205","DOIUrl":"https://doi.org/10.1515/pp-2022-0205","url":null,"abstract":"<p><strong>Objectives: </strong>Appendiceal cancer is a rare malignancy, occurring in roughly 1.2 per 100,000 per year. Low grade appendiceal neoplasams (LAMN) in particular can lead to pseudomyxoma peritonei (PMP), and respond poorly to systemic chemotherapy. Standard treatment includes cytoreduction surgery (CRS) with addition of heated intraoperative peritoneal chemotherapy (HIPEC). Several centres include early postoperative intraperitoneal chemotherapy (EPIC) however; the literature is mixed on the benefits. We aim to examine the benefits of additional EPIC through a propensity-matched analysis.</p><p><strong>Methods: </strong>Patients with LAMN with PMP who underwent cytoreductive surgery at St George hospital between 1996 and 2020 were included in this retrospective analysis. Propensity score matching was performed with the following used to identify matched controls; sex, age, American Society of Anesthesiologists (ASA) grade, peritoneal cancer index (PCI) and morbidity grade. Outcomes measured included length of stay and survival.</p><p><strong>Results: </strong>A total of 224 patients were identified of which 52 received HIPEC alone. Propensity matching was performed to identify 52 matched patients who received HIPEC + EPIC. Those receiving HIPEC + EPIC were younger at 54.3 vs. 58.4 years (p=0.044). There was a median survival benefit of 34.3 months for HIPEC + EPIC (127.3 vs. 93.0 months, p=0.02). Median length of stay was higher in those who received EPIC (25.0 vs. 23.5 days, p=0.028).</p><p><strong>Conclusions: </strong>In LAMN with PMP, the addition of EPIC to HIPEC with CRS improves overall survival in propensity score matched cases but results in prolonged hospitalisation. The use of EPIC should still be considered in selected patients.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 1","pages":"27-35"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9336169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erector spinae plane blocks for day-case medical thoracoscopy: a pilot clinical study.","authors":"Jamie McPherson,&nbsp;Edward Halvey,&nbsp;Avinash Aujayeb","doi":"10.1515/pp-2022-0115","DOIUrl":"https://doi.org/10.1515/pp-2022-0115","url":null,"abstract":"<p><strong>Objectives: </strong>Erector spinae plane (ESP) blocks are a regional anaesthetic technique used for pain relief in thoracic procedures. Our centre has recently begun using ESP blocks pre-medical thoracoscopy for analgesia.</p><p><strong>Methods: </strong>Nine patients undergoing MT from September 2021 to February 2022 were included. Opioid use and depth of required sedation was recorded. Pre and post pain scores and at home were recorded by interview and review of charts. A functional pain questionnaire was administered via telephone.</p><p><strong>Results: </strong>Average greatest depth of sedation using propofol was 1.92 (standard error of mean [SEM] 0.27), with remifentanil 2.52 (SEM 0.46). 78% required oral analgesia on day 0 post discharge. 55% required oral analgesia on post-op day 1. Patients used an average of 3.33 mg oral morphine (SEM 2.35) in hospital, and 3 mg (SEM 2) on post-op day 1. Periprocedural pain scores were 0.66 (SEM 0.27). Pain scores in recovery were 1.56 (SEM 0.76). Pain scores 3-12 h post discharge were 3.56 (SEM 0.7), while pain scores on post-op day 1 were significantly higher at 5.56 (SEM 0.90) (Figure 1). Functional pain scoring showed patients doing activities of daily living well with a good ability to breathe and cough. All felt that their pain was well controlled on the day of the procedure and at home. No complications were reported.</p><p><strong>Conclusions: </strong>ESP blocks provide good analgesia. Pain scores showed significant analgesic effect lasting several hours. The project showed pain outcomes and patient acceptability were good for the use of regional anaesthesia.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 4","pages":"187-190"},"PeriodicalIF":1.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytologic features of epithelioid gastrointestinal stromal tumor in a pleural effusion. A diagnostic challenge.","authors":"Mariel Valdivia-Mazeira,&nbsp;Carlos Gordillo,&nbsp;Zehra Avan,&nbsp;Lidia Castillo-Gázquez,&nbsp;José A Jiménez-Heffernan","doi":"10.1515/pp-2022-0196","DOIUrl":"https://doi.org/10.1515/pp-2022-0196","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 4","pages":"191-193"},"PeriodicalIF":1.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review.","authors":"Vicky Chen,&nbsp;Morgan Jones,&nbsp;Lauren Cohen,&nbsp;Wilson Yang,&nbsp;Jasman Bedi,&nbsp;Helen M Mohan,&nbsp;Sameer S Apte,&nbsp;José Tomas Larach,&nbsp;Michael Flood,&nbsp;Alexander Heriot,&nbsp;Joseph Kong,&nbsp;Satish Warrier","doi":"10.1515/pp-2022-0121","DOIUrl":"https://doi.org/10.1515/pp-2022-0121","url":null,"abstract":"<p><strong>Objectives: </strong>Small bowel adenocarcinoma (SBA) with peritoneal metastasis (PM) is rare and despite treatment with systemic chemotherapy, the prognosis is poor. However, there is emerging evidence that cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a survival benefit over systemic therapy alone. This systematic review will assess the effectiveness of CRS-HIPEC for SBA-PM.</p><p><strong>Content: </strong>Three databases were searched from inception to 11/10/21. Clinical outcomes were extracted and analysed.</p><p><strong>Summary: </strong>A total of 164 cases of SBA-PM undergoing CRS-HIPEC were identified in 12 studies. The majority of patients had neoadjuvant chemotherapy (87/164, 53%) and complete cytoreduction (143/164, 87%) prior to HIPEC. The median overall survival was 9-32 months and 5-year survival ranged from 25 to 40%. Clavien-Dindo grade III/IV morbidity ranged between 19.1 and 50%, while overall mortality was low with only 3 treatment-related deaths.</p><p><strong>Outlook: </strong>CRS-HIPEC has the potential to improve the overall survival in a highly selected group of SBA-PM patients, with 5-year survival rates comparable to those reported in colorectal peritoneal metastases. However, the expected survival benefits need to be balanced against the intrinsic risk of morbidity and mortality associated with the procedure. Further multicentre studies are required to assess the safety and feasibility of CRS-HIPEC in SBA-PM to guide best practice management for this rare disease.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 4","pages":"159-167"},"PeriodicalIF":1.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design.","authors":"Mustafa Raoof,&nbsp;Kevin M Sullivan,&nbsp;Paul H Frankel,&nbsp;Marwan Fakih,&nbsp;Timothy W Synold,&nbsp;Dean Lim,&nbsp;Yanghee Woo,&nbsp;Isaac Benjamin Paz,&nbsp;Yuman Fong,&nbsp;Rebecca Meera Thomas,&nbsp;Sue Chang,&nbsp;Melissa Eng,&nbsp;Raechelle Tinsley,&nbsp;Richard L Whelan,&nbsp;Danielle Deperalta,&nbsp;Marc A Reymond,&nbsp;Jeremy Jones,&nbsp;Amit Merchea,&nbsp;Thanh H Dellinger","doi":"10.1515/pp-2022-0116","DOIUrl":"https://doi.org/10.1515/pp-2022-0116","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal metastasis (PM) from appendiceal cancer or colorectal cancer (CRC) has significant morbidity and limited survival. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a minimally invasive approach to treat PM. We aim to conduct a dose-escalation trial of mitomycin C (MMC)-PIPAC combined with systemic chemotherapy (FOLFIRI) in patients with PM from appendiceal cancer or CRC.</p><p><strong>Methods: </strong>This is a multicenter Phase I study of MMC-PIPAC (NCT04329494). Inclusion criteria include treatment with at least 4 months of first- or second-line systemic chemotherapy with ineligibility for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Exclusion criteria are: progression on chemotherapy; extraperitoneal metastases; systemic chemotherapy intolerance; bowel obstruction; or poor performance status (ECOG>2). Escalating MMC-PIPAC doses (7-25 mg/m²) will be administered in combination with standard dose systemic FOLFIRI. Safety evaluation will be performed on 15 patients (dose escalation) and six expansion patients: 21 evaluable patients total.</p><p><strong>Results: </strong>The primary endpoints are recommended MMC dose and safety of MMC-PIPAC with FOLFIRI. Secondary endpoints are assessment of response (by peritoneal regression grade score; Response Evaluation Criteria in Solid Tumors [RECIST 1.1], and peritoneal carcinomatosis index), progression free survival, overall survival, technical failure rate, surgical complications, conversion to curative-intent CRS-HIPEC, patient-reported outcomes, and functional status. Longitudinal blood and tissue specimens will be collected for translational correlatives including pharmacokinetics, circulating biomarkers, immune profiling, and single-cell transcriptomics.</p><p><strong>Conclusions: </strong>This Phase I trial will establish the recommended dose of MMC-PIPAC in combination with FOLFIRI. Additionally, we expect to detect an early efficacy signal for further development of this therapeutic combination.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 4","pages":"169-177"},"PeriodicalIF":1.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10275848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peritoneal regression grading score (PRGS) in peritoneal metastasis: how many biopsies should be examined?","authors":"Wiebke Solass,&nbsp;Christoph Meisner,&nbsp;Florian Kurtz,&nbsp;Giorgi Nadiradze,&nbsp;Marc A Reymond,&nbsp;Hans Bösmüller","doi":"10.1515/pp-2022-0118","DOIUrl":"https://doi.org/10.1515/pp-2022-0118","url":null,"abstract":"<p><strong>Objectives: </strong>The four-tied peritoneal regression grading score (PRGS) is increasingly used to evaluate the response of peritoneal metastases (PM) to chemotherapy. The minimal number of peritoneal biopsies needed for PRGS determination remains unclear.</p><p><strong>Methods: </strong>A prospective cohort of 89 PM patients treated with 210 pressurized intraperitoneal aerosol chemotherapy (PIPAC) cycles was investigated. Four biopsies from every abdominal quadrant were recommended. Histological tumor response was defined as a stable or decreasing mean PRGS between therapy cycles, progression increasing. We compared the diagnostic uncertainty induced by missing biopsies to the histological response.</p><p><strong>Results: </strong>A total of 49 patients had at least two PIPAC and were eligible for therapy response assessment. Mean PRGS decreased from 2.04 (CI 5-95% 1.85-2.27) to 1.79 (CI 5-95% 1.59-2.01), p=0.14, as a proof of therapy effectiveness. 35 (71.4%) patients had a stable or decreasing PRGS (therapy response), 14 (28.6%) a PRGS increase (disease progression). Histology showed agreement between four biopsies in 42/210 laparoscopies (20%), between ≥3 biopsies in 103 (49%), and between ≥2 biopsies in 169 laparoscopies (81%). Mean loss of information with one missing biopsy was 0.11 (95% CI=0.13) PRGS points, with two missing biopsies 0.18 (95% CI 0.21). In 9/49 patients (18.3%), the loss of information with one less biopsy exceeded the change in PRGS under therapy.</p><p><strong>Conclusions: </strong>A minimum of three biopsies is needed to diagnose PM progression with an accuracy superior to 80%. Missing biopsies often result in a false diagnosis of tumor progression.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 4","pages":"179-185"},"PeriodicalIF":1.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peritoneal metastases of unknown primary with hepatoid features.","authors":"Lakhdar Khellaf,&nbsp;Stéphanie Nougaret,&nbsp;Sébastien Carrère,&nbsp;Frédéric Bibeau","doi":"10.1515/pp-2022-0113","DOIUrl":"https://doi.org/10.1515/pp-2022-0113","url":null,"abstract":"A 59-year-old woman presented with isolated peritoneal metastases in the context of elevated serum AFP levels (Figure 1A and B). No primary tumour was found, notably from the liver, the gastrointestinal or gynecological tracts. A laparoscopic assessment reported a peritoneal cancer index (PCI) reaching 22/39 and biopsies performed disclosed hepatocellular carcinoma (HCC). A chemotherapy followed by Figure 1: Magnetic resonance imaging (MRI) of the liver and peritoneum (axial T2 weighted images). (A) Initial MRI: ill-defined T2 hyperintense nodule within the falciform ligament of the liver (arrow). (B) MRI at 3 months: Appearance of several peritoneal metastases (arrows). Note the absence of any parenchymal liver tumour in both images. (C) Histopathological analysis: hepatocellular carcinoma (asterisks) in the falciform ligament of the liver, representing the starting point of the peritoneal disease. Ectopic liver is circled in red (greater axis: 15 mm), with detectable steatosis (HES, ×6). Note the independent vasculo-biliary stalk, highlighted in the inset (HES, ×50). HES: hematoxylin-eosin-saffron.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"157-158"},"PeriodicalIF":1.8,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of prophylactic HIPEC in non-metastatic, serosa-invasive gastric cancer: a literature review.","authors":"Aditya R Kunte,&nbsp;Aamir M Parray,&nbsp;Manish S Bhandare,&nbsp;Sohan Lal Solanki","doi":"10.1515/pp-2022-0104","DOIUrl":"https://doi.org/10.1515/pp-2022-0104","url":null,"abstract":"<p><p>The role of prophylactic hyperthermic intraperitoneal chemotherapy (p-HIPEC) in serosa invasive gastric cancers without gross or microscopic peritoneal disease, to reduce the rate of peritoneal relapse is an area of ongoing research. Although p-HIPEC is effective in reducing the rate of peritoneal relapse and improving disease free and overall survival with or without adjuvant chemotherapy, when added to curative surgery in locally advanced, non-metastatic gastric cancers, the available literature is at best, heterogeneous, centre-specific and skewed. Apart from that, variations in the systemic therapy used, and the presence of the associated nodal disease further complicate this picture. To evaluate the role of p-HIPEC the PubMed, Cochrane central register of clinical trials, and the American Society of Clinical Oncology (ASCO) meeting library were searched with the search terms, \"gastric\", \"cancer\", \"hyperthermic\", \"intraperitoneal\", \"chemotherapy\", prophylactic\", \"HIPEC\" in various combinations, and a critical review of the available evidence was done. Although p-HIPEC is a promising therapy in the management of locally advanced gastric cancers, the current evidence is insufficient to recommend its inclusion into routine clinical practice. Future research should be directed towards identification of the appropriate patient subset and towards redefining its role with current peri-operative systemic therapies.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"103-115"},"PeriodicalIF":1.8,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne.","authors":"Francesco Casella,&nbsp;Maria Bencivenga,&nbsp;Riccardo Rosati,&nbsp;Uberto Romario Fumagalli,&nbsp;Daniele Marrelli,&nbsp;Fabio Pacelli,&nbsp;Antonio Macrì,&nbsp;Annibale Donini,&nbsp;Lorena Torroni,&nbsp;Michele Pavarana,&nbsp;Giovanni De Manzoni","doi":"10.1515/pp-2022-0111","DOIUrl":"https://doi.org/10.1515/pp-2022-0111","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal carcinomatosis is the most frequent site of metastases in patients with gastric cancer. Current standard treatment is palliative systemic chemotherapy with very poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in long-term benefits in selected patients. Among patients with peritoneal carcinomatosis, a distinctive subset is oligometastatic disease which is characterized by low metastatic burden. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a recent technique of intraperitoneal chemotherapy used in combination with systemic chemotherapy with promising results.</p><p><strong>Methods: </strong>PIPAC VER-One is a prospective, randomized, multicenter phase III clinical trial that aims to evaluate the effectiveness of the use of PIPAC in combination with systemic chemotherapy in patients with gastric cancer and synchronous positive peritoneal cytology and/or limited peritoneal metastases (peritoneal cancer index [PCI] ≤6). Patients will be randomized into two arms: arm A (control) treated with standard systemic chemotherapy and arm B (experimental) treated with a bidirectional scheme including PIPAC and systemic chemotherapy.</p><p><strong>Results: </strong>Primary endpoint is the secondary resectability rate. Secondary endpoints are: overall survival (OS), pregression-free survival (PFS), disease-free survival (DFS), histological response assessed both on primary tumor and peritoneal lesions, quality of life (QoL), complication rate (CTCAE v5), and incremental cost-effectiveness ratios (ICER).</p><p><strong>Conclusions: </strong>The role of PIPAC in multimodal treatment for oligometastatic gastric cancer will be investigated in this trial.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 3","pages":"135-141"},"PeriodicalIF":1.8,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33484288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}